SPRB
Spruce Biosciences Inc
$
9.080
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
9.640
Open
8.7499
VWAP
8.74
Vol
16.44K
Mkt Cap
5.11M
Low
8.200
Amount
143.58K
EV/EBITDA(TTM)
--
Total Shares
41.15M
EV
-10.73M
EV/OCF(TTM)
--
P/S(TTM)
203.45
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for neurological disorders with significant unmet medical need. The Company has acquired an exclusive worldwide license agreement for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). The TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) with modified human insulin-like growth factor 2 via an amino acid linker. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. The Company's pipeline also includes Tildacerfont and Cortibon for the treatment of Major Depressive Disorder, SPR202 for the treatment of Congenital Adrenal Hyperplasia and SPR204 for the treatment of Post-Bariatric Hypoglycemia.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
0.00
-100%
-20.250
+22.73%
0.00
-100%
-18.000
+14.29%
--
--
-16.500
-61.4%
Estimates Revision
The market is revising No Change the revenue expectations for Spruce Biosciences, Inc. (SPRB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -7.35%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Down
-7.35%
In Past 3 Month
1 Analyst Rating
Wall Street analysts forecast SPRB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SPRB is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
Current: 9.080
Low
10.00
Averages
10.00
High
10.00
Current: 9.080
Low
10.00
Averages
10.00
High
10.00
RBC Capital
Gregory Renza
Hold
Maintains
$1.5 → $0.5
2025-04-16
Reason
RBC Capital
Gregory Renza
Price Target
$1.5 → $0.5
2025-04-16
Maintains
Hold
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Hold
Reiterates
n/a
2024-12-16
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
n/a
2024-12-16
Reiterates
Hold
Reason
Guggenheim
Evan Wang
Hold
Reiterates
n/a
2024-12-12
Reason
Guggenheim
Evan Wang
Price Target
n/a
2024-12-12
Reiterates
Hold
Reason
Oppenheimer
Hartaj Singh
Buy
to
Hold
Downgrades
n/a
2024-12-11
Reason
Oppenheimer
Hartaj Singh
Price Target
n/a
2024-12-11
Downgrades
Buy
to
Hold
Reason
Oppenheimer downgraded Spruce Biosciences to Perform from Outperform without a price target. The company announced disappointing topline results from both of its ongoing trials of tildacerfont, the analyst tells investors in a research note. The firm awaits clarity on next steps with Spruce winding down both trials and prioritizing cash conservation as it evaluates strategic alternatives.
RBC Capital
Gregory Renza
Hold
Reiterates
$2 → $1.5
2024-12-11
Reason
RBC Capital
Gregory Renza
Price Target
$2 → $1.5
2024-12-11
Reiterates
Hold
Reason
JMP Securities
Jonathan Wolleben
Buy
to
Hold
Downgrades
$3
2024-12-11
Reason
JMP Securities
Jonathan Wolleben
Price Target
$3
2024-12-11
Downgrades
Buy
to
Hold
Reason
JMP Securities downgraded Spruce Biosciences to Market Perform from Outperform without a price target. The firm is stepping to the sidelines after tildacerfont missed in the Phase 2b CAHmelia-204 trial. Despite some evidence of more effective twice-daily doses in the Phase 2 CAHptain-205 trial, the data apparently are not convincing enough for further investment in congenital adrenal hyperplasia, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Spruce Biosciences Inc (SPRB.O) is -6.95, compared to its 5-year average forward P/E of -2.44. For a more detailed relative valuation and DCF analysis to assess Spruce Biosciences Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-2.44
Current PE
-6.95
Overvalued PE
0.45
Undervalued PE
-5.34
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-1.11
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.23
Undervalued EV/EBITDA
-4.46
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
-64.14
Current PS
0.00
Overvalued PS
238.53
Undervalued PS
-366.80
Financials
Annual
Quarterly
FY2025Q2
YoY :
-100.00%
0.00
Total Revenue
FY2025Q2
YoY :
-73.18%
-2.69M
Operating Profit
FY2025Q2
YoY :
-77.49%
-2.07M
Net Income after Tax
FY2025Q2
YoY :
+1467.54%
-262.25
EPS - Diluted
FY2025Q1
YoY :
-100.00%
N/A
Free Cash Flow
FY2025Q1
YoY :
-100.00%
N/A
Gross Profit Margin - %
FY2025Q1
YoY :
-100.00%
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
SPRB News & Events
Events Timeline
2025-07-22 (ET)
2025-07-22
10:37:04
Spruce, HMNC Brain Health announce first patient dosed in Phase 2 TAMARIND trial
2025-04-15 (ET)
2025-04-15
07:07:16
Spruce acquires tralesinidase alfa enzyme replacement therapy
2024-11-11 (ET)
2024-11-11
07:05:24
Spruce Biosciences reports Q3 EPS (21c), consensus (24c)
Sign Up For More Events
Sign Up For More Events
News
2.0
09-15SeekingAlphaSpruce Biosciences Restarts Nasdaq Trading with Shares Rising More Than 40%
2.0
08-04TipRanksUpcoming Stock Splits This Week (August 4 to August 8) – Stay Invested
9.0
07-22GlobenewswireHMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder
Sign Up For More News
People Also Watch
FLYE
Fly-E Group Inc
1.010
USD
+33.78%
CVR
Chicago Rivet & Machine Co
10.780
USD
-0.74%
BBGI
Beasley Broadcast Group Inc
5.593
USD
-4.72%
CLRO
Clearone Inc
5.630
USD
+4.45%
AIRI
Air Industries Group
3.090
USD
+0.32%
DTSS
Datasea Inc
2.140
USD
+3.13%
CDTG
CDT Environmental Technology Investment Holdings Ltd
0.830
USD
-2.58%
YHGJ
Yunhong Green CTI Ltd
0.546
USD
-1.44%
RMCF
Rocky Mountain Chocolate Factory Inc (Delaware)
1.730
USD
-10.82%
TRIB
Trinity Biotech PLC
1.195
USD
+0.42%
FAQ
What is Spruce Biosciences Inc (SPRB) stock price today?
The current price of SPRB is 9.08 USD — it has increased 8.42 % in the last trading day.
What is Spruce Biosciences Inc (SPRB)'s business?
What is the price predicton of SPRB Stock?
What is Spruce Biosciences Inc (SPRB)'s revenue for the last quarter?
What is Spruce Biosciences Inc (SPRB)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Spruce Biosciences Inc (SPRB)'s fundamentals?
How many employees does Spruce Biosciences Inc (SPRB). have?